Basilea Pharmaceutica has announced the receipt of its first commercial milestone payment of CHF1.2m from partner Asahi Kasei Pharma (AKP) for reaching an undisclosed sales threshold in Japan for its lead anti-infective drug Cresemba. Japan, along with China, are key new markets for Cresemba, making up c 25% of the drug’s global potential. Cresemba recorded global in-market sales of US$533m in the 12-month period ending September 2024, at a 20% y-o-y growth rate. Importantly, unlike the US and European markets, where Cresemba is approaching maturity (market protection up to Q427), Japan is a fairly new entry for Cresemba (launched in January 2024, triggering a CHF5m development milestone from AKP), which comes with significantly longer exclusivity period and should support lifecycle management.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment